Alder BioPharmaceuticals Announces Presentations at 69th Annual American Academy of Neurology Meeting Supporting Development ...
March 06 2017 - 7:00AM
Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage
biopharmaceutical company developing monoclonal antibody
therapeutics, today announced that data for eptinezumab (formerly
ALD403), which is in clinical development for the prevention of
migraine, will be presented at the upcoming 69th Annual American
Academy of Neurology meeting on April 22-28, 2017 in Boston.
- Platform presentation: Randomized, Double-Blind,
Placebo-Controlled Trial of ALD403, an Anti-CGRP Peptide Antibody
in the Prevention of Chronic MigraineSession: S52, Headache:
Clinical Trials and Disease Burden Date: Friday, April 28,
2017 Presenter: Dr. David Dodick Time: 1:24 p.m. Location:
Boston Convention and Exhibition Center
- Poster presentation: Rational Design of a Monoclonal Antibody
(mAb) Inhibiting Calcitonin Gene-Related Peptide (CGRP), ALD403,
Intended for the Prevention of MigrainePoster: #155 Date: Monday,
April 24 Poster Q & A Session: 5:30 p.m. – 7:00 p.m. EDT
Location: Boston Convention and Exhibition Center, Poster
Session II
- Poster presentation: 75% Responder Rates Provide Improvement in
HIT-6 Scores from Week 4 Through 12 Following a Single Infusion of
ALD403, or Placebo Poster: #165 Date: Monday, April
24 Poster Q & A Session: 5:30 p.m. – 7:00 p.m.
EDT Location: Boston Convention and Exhibition Center, Poster
Session II
About Alder
BioPharmaceuticals
Alder BioPharmaceuticals, Inc., is a clinical-stage
biopharmaceutical company that discovers, develops and seeks to
commercialize genetically engineered therapeutic antibodies with
the potential to meaningfully transform current treatment
paradigms. Alder's lead pivotal-stage product candidate,
eptinezumab, is being evaluated for migraine prevention.
Eptinezumab is a monoclonal antibody that inhibits calcitonin
gene-related peptide (CGRP), a protein that is active in mediating
the initiation of migraine. Alder is additionally evaluating
ALD1910, a preclinical product candidate also in development as a
migraine prevention therapy. ALD1910 is a monoclonal antibody that
inhibits pituitary adenylate cyclase-activating polypeptide-38
(PACAP-38), another protein that is active in mediating the
initiation of migraine. Clazakizumab, Alder's third program, is a
monoclonal antibody candidate that inhibits interleukin-6 and is
licensed to Vitaeris, Inc. For more information, please visit
http://www.alderbio.com.
Media Contacts:
David Schull or Victoria Meissner
Russo Partners, LLC
(212) 845-4271
(646) 942-5627
david.schull@russopartnersllc.com
victoria.meissner@russopartnersllc.com
Investor Relations Contact:
David Walsey
Alder BioPharmaceuticals Inc.
(425) 408-8032
ir@alderbio.com
Alder BioPharmaceuticals (NASDAQ:ALDR)
Historical Stock Chart
From Apr 2024 to May 2024
Alder BioPharmaceuticals (NASDAQ:ALDR)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Alder BioPharmaceuticals Inc (NASDAQ): 0 recent articles
More News Articles